GABA(B) receptor agonist only reduces ethanol drinking in light-drinking mice


Autoria(s): Villas Boas, Gustavo Roberto; Zamboni, Camila Gadens; Peretti, Murilo Calvo; Correia, Diego; Rueda, André Veloso Lima; Camarini, Rosana; Brunialti-Godard, Ana Lucia; Boerngen-Lacerda, Roseli
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

07/11/2013

07/11/2013

2012

Resumo

Baclofen, a GABA(B) agonist, reduces ethanol intake in animals and humans, but the contrary or no effect was also reported. Our previous study demonstrated that mice characterized as "loss of control over ethanol intake" had different Gabbr1 and Gabbr2 transcription levels, which express, respectively, the GABA(B1) and GABA(B2) subunits in brain areas related to addictive behavior. In the present study, we tested baclofen on ethanol intake in mice exposed to the free-choice paradigm. Adult male Swiss mice, individually housed, had free access to three bottles: ethanol (5% and 10%) and water. The protocol had four phases: acquisition (AC, 10 weeks), withdrawal (W, 4 cycles during 2 weeks of 2 day-free-choice and 2 day-only-water), reexposure (RE, 2 weeks), and adulteration of ethanol solutions with quinine (AD, 2 weeks). Mice characterized as "loss of control" (A, n = 11, preference for ethanol in AC and maintenance of ethanol intake levels in AD), heavy (H, n = 11, preference for ethanol in AC and reduction of ethanol intake levels in AD), and light (L n = 16, preference for water in all phases) drinkers were randomly distributed into two subgroups receiving either intraperitoneal injections of all doses of baclofen (1.25, 2.5, and 5.0 mg/kg, given each dose twice in consecutive days) or saline, being exposed to free-choice. Fluid consumption was measured 24 h later. Baclofen reduced ethanol intake in group L In group H a reduction compared to AC was observed. Group A maintained their high ethanol intake even after baclofen treatment. Activation of the GABA(B) receptor depends on the precise balance between the GABA(B1) and GABA(B2) subunits, so the disproportionate transcription levels, we reported in group A, could explain this lack of response to baclofen. These data highlight the importance to test baclofen in individuals with different ethanol drinking profiles, including humans. (C) 2012 Elsevier Inc. All rights reserved.

Universidade Federal do Parana

Universidade Federal do Parana

Conselho de Auxilio do Pessoal de Ensino Superior (CAPES)

Conselho de Auxilio do Pessoal de Ensino Superior (CAPES)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Identificador

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, OXFORD, v. 102, n. 2, supl., Part 3, pp. 233-240, AUG, 2012

0091-3057

http://www.producao.usp.br/handle/BDPI/43284

10.1016/j.pbb.2012.04.011

http://dx.doi.org/10.1016/j.pbb.2012.04.011

Idioma(s)

eng

Publicador

PERGAMON-ELSEVIER SCIENCE LTD

OXFORD

Relação

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Direitos

closedAccess

Copyright PERGAMON-ELSEVIER SCIENCE LTD

Palavras-Chave #ADDICTION #BACLOFEN #ETHANOL #FREE-CHOICE PARADIGM #GABA(B) RECEPTOR #MICE #ALCOHOL-PREFERRING RATS #CENTRAL-NERVOUS-SYSTEM #ANIMAL-MODELS #SEEKING BEHAVIOR #PLACE PREFERENCE #ADDICTION MODEL #DRUG-ADDICTION #C57BL/6J MICE #BACLOFEN #COCAINE #BEHAVIORAL SCIENCES #NEUROSCIENCES #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion